logo-loader

Day One Biopharmaceuticals stock rallies as 1Q results show the brain tumor treatment candidate producer is funded into 2025

Published: 14:32 01 May 2023 EDT

Brain images being touched

Day One Biopharmaceuticals stock added more than 16% Monday afternoon after the company posted its first-quarter financial results. 

The Brisbane, California company reported a cash position of $318.2 million as of March 31, which management believes is sufficient to fund operations into 2025.

Research and development costs were $27.8 million, compared to $15 million in the same period of 2022. The uptick was due to additional employee compensation costs, as well as clinical trial and pre-commercial manufacturing activities related to the company’s lead brain tumor treatment candidate, tovorafenib.

Day One stock improved 16% to $14.39.

“We are excited about our upcoming milestones, including the opportunity to share new clinical data from the FIREFLY-1 trial in an oral presentation at ASCO,” CEO Jeremy Bender said in a statement. 

Day One’s net loss was $42.4 million in the quarter, with a non-cash stock compensation expense of $9.4 million, compared to $27.7 million with a non-cash stock compensation expense of $6.2 million a year earlier.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Arrow Exploration CEO on Icaco success, record production and next drilling...

Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) CEO Marshall Abbott talked with Proactive's Stephen Gunnion about the company's latest drilling success at Icaco in Colombia, where the IC-HZ9 well has exceeded production expectations and helped lift corporate output above 7,000 barrels of...

5 hours, 47 minutes ago